BiotechTube

Quadravalent human papillomavirus vaccine

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Late Complication From Kidney Transplant

Conditions

Late Complication From Kidney Transplant, Complication of Transplanted Liver, Human Papillomavirus-Related Carcinoma

Trial Timeline

Oct 1, 2013 → Dec 1, 2017

NCT ID
NCT02624349

About Quadravalent human papillomavirus vaccine

Quadravalent human papillomavirus vaccine is a approved stage product being developed by Merck for Late Complication From Kidney Transplant. The current trial status is completed. This product is registered under clinical trial identifier NCT02624349. Target conditions include Late Complication From Kidney Transplant, Complication of Transplanted Liver, Human Papillomavirus-Related Carcinoma.

What happened to similar drugs?

7 of 20 similar drugs in Late Complication From Kidney Transplant were approved

Approved (7) Terminated (3) Active (10)
✅FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
✅FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
✅Sarpogrelate Sustained Release/Aspirin + AspirinYuhanApproved
🔄olmesartan medoxomil + hydrochlorothiazide, if necessary + nitrendipine + hydrochlorothiazide, if necessaryDaiichi SankyoPhase 3
❌E10030 + ranibizumab + E10030 sham intravitreal injectionAstellas PharmaPhase 3
✅Basiliximab, Tacrolimus, MMF, Prednisolon + Basiliximab, Tacrolimus, MMF + Tacrolimus, MMF, rATGAstellas PharmaApproved
❌E10030 + bevacizumab or aflibercept + E10030 sham injectionAstellas PharmaPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02624349ApprovedCompleted

Competing Products

20 competing products in Late Complication From Kidney Transplant

See all competitors
ProductCompanyStageHype Score
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
33
FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
33
AL001 + PlaceboAlectorPhase 2
17
89Zr-DFO-AP-101Eli LillyPhase 1
33
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
Sarpogrelate Sustained Release/Aspirin + AspirinYuhanApproved
43
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
olmesartan medoxomil + hydrochlorothiazide, if necessary + nitrendipine + hydrochlorothiazide, if necessaryDaiichi SankyoPhase 3
40
Fovista® + bevacizumab + ranibizumab + afliberceptAstellas PharmaPhase 2
27
MA09-hRPEAstellas PharmaPre-clinical
26
volociximabAstellas PharmaPhase 1
29
Avacincaptad PegolAstellas PharmaPhase 1
29
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
27
Avacincaptad PegolAstellas PharmaPhase 1
29
E10030 + ranibizumab + E10030 sham intravitreal injectionAstellas PharmaPhase 3
32
E10030Astellas PharmaPhase 1
29
Basiliximab, Tacrolimus, MMF, Prednisolon + Basiliximab, Tacrolimus, MMF + Tacrolimus, MMF, rATGAstellas PharmaApproved
43